ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks
ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded…